Ardelyx Inc (41X.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
At close: 09:21PM CEST
| Previous Close | 5.48 |
| Open | 5.44 |
| Bid | 5.51 x 0 |
| Ask | 5.56 x 0 |
| Day's Range | 5.44 - 5.51 |
| 52 Week Range | 3.09 - 9.46 |
| Volume | |
| Avg. Volume | 238 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Oct 29, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GuruFocus.comArdelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges
Ardelyx Inc (ARDX) reports significant revenue growth amid strategic hurdles, with a focus on expanding market access for XPHOZAH.
Simply Wall St.Even though Ardelyx (NASDAQ:ARDX) has lost US$210m market cap in last 7 days, shareholders are still up 352% over 3 years
Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders might be concerned after seeing the share price drop 13% in the last week...
GlobeNewswireArdelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recent publication of a review article, titled “Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome With Constipation in the United States” in Clinical and Experimental Gastroenterology, an internati
© 2024 Yahoo. All rights reserved.